The possible mechanisms for the role of sacubitril/valsartan in DM, in addition to the related effects of inhibiting the renin-angiotensin system, include decreasing the degradation of active peptides that can lower glycaemia by inhibiting neprilysin, and improving glucolipid metabolism and insulin resistance by consuming excessive energy by increasing natriuretic peptides [13–15]. Here, MME is linked to diabetes mellitus.